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The annual deep brain stimulation (DBS) Think Tank aims to create an opportunity for
a multidisciplinary discussion in the field of neuromodulation to examine developments,
opportunities and challenges in the field. The proceedings of the Sixth Annual Think Tank
recapitulate progress in applications of neurotechnology, neurophysiology, and emerging
techniques for the treatment of a range of psychiatric and neurological conditions
including Parkinson’s disease, essential tremor, Tourette syndrome, epilepsy, cognitive
disorders, and addiction. Each section of this overview provides insight about the
understanding of neuromodulation for specific disease and discusses current challenges
and future directions. This year’s report addresses key issues in implementing advanced
neurophysiological techniques, evolving use of novel modulation techniques to deliver
DBS, ans improved neuroimaging techniques. The proceedings also offer insights into
the new era of brain network neuromodulation and connectomic DBS to define and
target dysfunctional brain networks. The proceedings also focused on innovations in
applications and understanding of adaptive DBS (closed-loop systems), the use and
applications of optogenetics in the field of neurostimulation and the need to develop
databases for DBS indications. Finally, updates on neuroethical, legal, social, and policy
issues relevant to DBS research are discussed.
Keywords: deep brain stimulation, neuromodulation, epilepsy, Parkinson’s disease, tremor, optogenetics,
Tourette syndrome, temporal dispersion
INTRODUCTION
Neuromodulation of brain structures and functions is an evolving
field. Ongoing scientific and technological advancements have
facilitated an improved understanding of brain networks and the
neural signals involved in the signs and symptoms of a number of
neuropsychiatric conditions. Novel methods of electrical current
delivery have been recently applied to existing neuromodulation
techniques in order to improve the understanding and the ability
to more precisely affect mechanisms, function and to influence
cortical and subcortical structures. The deep brain stimulation
(DBS) Think Tank is an annual forum that facilitates discussion
and debate about the latest scientific, technological, ethico-legal
issues, social innovations, challenges, and opportunities in the
field. The Sixth Annual DBS Think Tank was held in Atlanta,
GA, United States from 6 to 8 May, 2018. The meeting focused
on the use of novel modulation techniques and emerging areas
of scientific, technological, ethical, and policy development.
Specifically, the meeting addressed issues and possibilities of
modulating different neuronal networks; expanding capabilities
of responsive (closed-loop) DBS systems; and the therapeutic
potential of targeted brain network modulation. Particular
emphasis was placed upon advances and gaps in knowledge
of and capabilities to affect brain electrophysiology, interface
optogenetics and DBS, and on the multiple (technical, ethical,
policy, and social) factors that can limit and/or de-limit these
domains. We divided current proceedings in seven separate
sections discussing advances in the field as follows: connectomic
and network neuromodulation, advances in neurophysiological
signals for DBS, new neuromodulation techniques, applications
of optogenetic techniques in DBS, databases for DBS, and
neuroethical, Legal and social issues in DBS.
Brain Network Neuromodulation and
Connectomic DBS
Leveraging Human Brain Connectomics to
Improve DBS
Different stereotactic techniques are commonly used to
assure proper localization of subthalamic (STN-DBS) leads in
Parkinson’s disease (PD), including anatomical neuroimaging
and indirect stereotactic methods. However, therapeutic benefits
are likely the result of engagement and modulation of other
brain regions that are interactive with specific stimulation sites
and networks (Henderson, 2012; Fox et al., 2014). An improved
understating of brain node and network connectivity could
therefore be useful and of value to predicting and to optimizing
DBS responses and outcomes (Horn et al., 2017). Using diffusion
tractography, white matter tracts near the DBS electrode can be
accurately identified (Coenen et al., 2011; Pouratian et al., 2011;
Riva-Posse et al., 2014) and functional connectivity – a measure
of the correlation in spontaneous activity – can be used to link
subcortical DBS sites to effects in cortical regions (Anderson
et al., 2011; Fox et al., 2014).
Recent works highlight the importance of modulating the
hyperdirect pathway (connecting the STN to cortex) in the
effectiveness of STN-DBS (Gradinaru et al., 2009; Accolla et al.,
2016). Utilizing high-quality connectome datasets [diffusion
tractography and functional connectivity from normal subjects
(n = 1,030) and PD patients (n = 90)] Horn et al. (2017)
were able to compute connectivity profiles of beneficial STN
DBS for PD. There is a distinct pattern of connectivity with
STN DBS electrodes, which directly correlated with clinical
outcome. Importantly, structural and functional connectivity
independently predicted DBS response.
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Similarly, this technique can be used to explore or refine
DBS targets and theoretically to avoid or reduce side effects of
neuromodulation (Calabrese, 2016). Cognitive side effects are
possible after STN-DBS. Witt et al. (2013) assessed the influence
of cortical lead entry point, electrode path and position of
stimulating electrode contacts on neuropsychological changes
after surgery in patients with mild cognitive and semantic
fluency decline. When trajectories intersected with the caudate
nuclei, there was an increased risk of decline in cognition
and decrements in working memory. However, these results
need to be corroborated with additional larger and prospective
studies. Additionally, subjects who showed a decline in semantic
verbal fluency had the active electrode located outside the
dorsolateral stimulation STN, and connectivity profiles showed
clear differences between patients.
This technique can also be used in DBS treatment of other
conditions. For example, chronic-progressive gait ataxia in
patients with essential tremor (ET) can be reversed following
prolonged DBS washout, and is likely due to a stimulation-
induced vestibulo-cerebellar network dysfunction (Reich et al.,
2016). Using volume of tissue activated (VTA) modeling, it was
shown that stimulation of the more posteromedial and caudal
zones of the thalamus might account for this side effect, and
thus, avoiding a caudal and ventral placement might prevent
such chronic side effects. Further validation of these datasets
and findings is needed so that individualized DBS targets can
be evermore precisely estimated using network assessments to
minimize side effects.
Connectivity Underlies Antidepressant Response to
Subcallosal Cingulate DBS
Deep brain stimulation of the subcallosal cingulate (SCC) has
recently shown promise for the treatment of therapy-resistant
depression (Mayberg et al., 2005; Holtzheimer et al., 2012;
Puigdemont et al., 2012), acting via modulation of specific
pathological circuits. However, one of the remaining challenges is
a lack of biomarkers and feedback to enable confirmation of the
intended brain target. Therefore, attempts to develop a biometric
of signal propagation from a novel white matter target in the SCC
region are ongoing by exploiting stimulation evoked potentials
as a biomarker of effective connectivity. In a recent study, four
subjects were implanted in the SCC with the aid of StimVision
(Noecker et al., 2018). Electroencephalographic (EEG) recordings
were performed with DBS that was directed to the SCC white
matter region using 2 Hz settings at 6 V. The stimulation pulse
width was 90 microseconds (µs) and current was placed in a
monopolar configuration. Therapeutic stimulation of 130 Hz;
3–5 V; 90 µs was resumed after the recordings were collected.
A SCC DBS evoked potential (p40) was consistently elicited
and detected over a period of 14 months (at four time points)
(Figure 1). These results indicated that it was feasible to obtain
feedback on cortical responsivity by employing a stimulation
evoked potential, which can be used as a signal of optimal
targeting and test–retest reliability over time. This study indicated
that the p40 feature may be an activation of the forceps minor,
which was consistent with previous data that linked stimulation
evoked response to white matter activation (Waters et al., 2018).
Targeting Identified Brain Connections With DBS
As previously stated, it is becoming increasingly evident that the
benefits of DBS for disorders such as ET and PD depend on the
connectivity of the site of stimulation with other brain networks
and regions (Horn et al., 2017; Malekmohammadi et al., 2018b).
Insights into the connectivity of effective therapeutic stimulation
(in comparison to ineffective stimulation) will likely enhance the
ability to target deep brain structures. This could also improve
the ability to develop new DBS surgical methods (such as asleep
image-guided implantation, although this procedure has been
performed successfully without connectivity data in many centers
for years), technologies (that more precisely produce network-
based neuromodulation), and therapeutic indications (such
as treatment-resistant depression and other neuropsychiatric
disorders including addiction; as well as certain forms of
intractable pain).
Methods for evaluating connectivity include both
anatomical (diffusion tensor imaging and tractography)
and functional techniques [EEG, functional MRI, and invasive
neurophysiological techniques including microelectrode
recordings, local field potentials (LFPs), and electrocorti-
cography]. One of the earliest demonstrations of such DBS
targeting was the application of connectivity-based thalamic
segmentation, which revealed discrete thalamic regions with
distinctive connectivity patterns with cortical regions (Pouratian
et al., 2011). Subsequent reports have elaborated on the value
of tractography for thalamic targeting, using methods to both
directly target the region-of-interest in the thalamus (Sasada
et al., 2017; Tsolaki et al., 2018) as well as for indirect targeting,
in which adjacent tracts which should be avoided are delineated
(Sammartino et al., 2016). An alternate method would entail
mapping the pyramidal tracts and medial lemniscus, and
targeting DBS placements that are medial and anterior to
these tracts, respectively (Sammartino et al., 2016). The most
efficacious DBS contact for tremor control is localized within
the thalamic region connected to the premotor, rather than
the primary motor cortex as would be predicted by traditional,
preoperative, indirect targeting methods. In ET patients,
diffusion tensor imaging (DTI) based fiber tractography can
aid in determining the optimal target(s) to maximally achieve
tremor suppression and to reduce the number of adverse events
by avoiding stimulation or lesioning of other nearby tracts,
respectively (Sasada et al., 2017). Analyzing four fiber tracts
important for motor control, tractography revealed a strong role
of the cerebello thalamic and pre motor cortex modulation in ET
patients with thalamotomy or thalamic DBS. It was observed that
those fiber afferents from the cerebellum that passed through
ventral intermedius nucleus (VIM) and the area anterior to the
VIM were likely connected to the pre motor or motor cortex.
In another study, probabilistic tractography-guided thalamic
targeting was employed to treat ET (Tsolaki et al., 2018): MR
imaging and clinical outcomes following thalamotomy (MR
guided- Focus ultrasound) were assessed. Thalamic connectivity
to pre- and post-central gyral targets was evaluated and
individual thalamic target maps were generated. Using receiver
operating characteristic curves to define overlapping thalamic
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FIGURE 1 | (A) SCC DBS evoked potentials in patients with treatment resistant depression may also be useful. It is less important to hit the visible target; it is more
about hitting the correct portion of the connectome. (B) Use DTI: to target structures intraoperatively. (C) Record LFP at the DTI-optimized target. (D) Use high-
density EEG: to detect evoked cortical responses for stimulation. This figure adapted from Cho et al. (2017).
maps, the overlap between these thalamic target maps and
the MR guided- Focus ultrasound lesion was systematically
weighed with respect to clinical outcome, and the connectivity
differences of best clinical outcomes were compared. These
investigations demonstrated that the intersection between
lesion and thalamic-connectivity mapped to motor areas,
while sensory targets proved to be effective in predicting the
response to therapy.
While the use of tractography-guided thalamic targeting for
ET has been a powerful proof of concept, an additional practical
utility lies in the potential of using such approaches to either
optimize therapies that have been inconsistent to date, or to
develop novel applications. For example, thalamic DBS for pain
is associated with inconsistent efficacy, possibly due, in part, to
the lack of optimized targeting. To gain insight to the potential
value of tractography-guided thalamic DBS targeting for pain,
a small retrospective analysis of five patients was performed.
It was shown that the pain patients who derived benefit from
thalamic DBS for their pain had DBS leads that co-localized
with those thalamic regions with maximal connectivity with the
post-central gyrus (Kim et al., 2016). Looking ahead, it may
be important for the discipline to integrate knowledge about
stimulation fields, therapeutic outcomes, and tractography in
order to create clinically-weighted optimal connectivity maps
with which to define optimal stimulation targets (rather than to
identify and engage seed regions and targets based on predefined,
potentially arbitrary, anatomic segmentations; Tsolaki et al.,
2018). The idea of employing multiple methods to define target
site represents something of a reversal: rather than starting
with a hypothesis about the optimal network engagement,
this approach allows data-driven outcome-weighted delineation
of networks that may prove to be contributory to improved
therapeutic outcomes.
Other studies have investigated DBS targets other than
the thalamus. Investigators have mapped the hyperdirect
pathway from the primary motor cortex to STN, based on
the hypothesis that the optimal site of STN stimulation is
the site of hyperdirect pathway input. To further explore this
hypothesis, hyperdirect pathways and associated STN target
maps generated by two different tractography approaches
(i.e., tensor-based deterministic method, and an advanced
probabilistic method) were compared (Petersen et al.,
2017). Both identified connections between the ipsilateral
motor cortex and STN, but defined different target regions
in the STN. The probabilistic method, which is based
on constrained spherical deconvolution, resulted in a
reconstruction of motor cortical connections terminating
in the dorsolateral STN, consistent with the optimal site
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FIGURE 2 | Network-based measures can be recorded during DBS surgery via the same burr hole utilized for DBS lead implantation. In these illustrations, the use of
an electrocorticography strip is shown. Simultaneous signals are recorded from the motor cortices while also recording through the DBS lead.
of stimulation. The tensor-based method resulted in a
reconstruction of fewer, and more variable connections.
Hence, the probabilistic method was considered to be more
consistent for STN mapping.
Brain networks can also be evaluated using both non-
invasive and invasive neurophysiologic methods (Figure 2).
There have been several reports of either measuring biosignals
in distinct nodes throughout a targeted network, or of
evaluation of network-based biosignals. An example of the
former is the detection of increased phase-amplitude coupling
in the precentral gyrus of patients with PD, which is
suppressed with therapeutic stimulation of both the STN
(De Hemptinne et al., 2015) and the GPi (Malekmohammadi
et al., 2018a). Another approach is to measure network
connectivity by evaluating the coupling of signals in and
across different nodes and to demonstrate modulation of
these network-wide signals. Using such methods, two groups
have recently demonstrated suppression of pallidocortical beta
coherence with effective pallidal DBS and changes in cortico-
subcortical functional connectivity were shown to be spatially
exclusive to the motor cortex (Malekmohammadi et al., 2018b;
Wang et al., 2018).
Individualized Network Interrogation and
Targeted DBS
Neuropsychiatric disorders are increasingly being viewed as
node and network-level brain dysfunctions. Apropos such a
perspective, there is renewed enthusiasm for understanding
the complex anatomical and functional bases of particular
neuropsychiatric states and conditions. Extant, simplistic
classifications of neuropsychiatric disorders based solely upon
patient signs and symptoms have been limited, at best, and
clinically ineffective and inefficient as worst, and therefore
a taxonomy based on orthogonalized axes of psychological
constructs and neural circuit dysfunction may be better suited
(and of greater value) in affording a more rational (and testable)
basis for developing new therapeutic methods and approaches,
inclusive of DBS.
A number of brain networks have been implicated in
depression, including those subserving the default mode,
salience, and negative affect (Williams, 2017). The concept of
targeting specific networks based on an individual biotype (e.g.,
neuropsychiatric phenotypes) remains an evolving construct,
which may be advanced by the use of advanced neuroimaging
to obtain neuroanatomical and neurophysiological information
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about individual patients. This may facilitate improved clinical
outcomes when using more saliently targeted DBS. In an
ongoing study (NCT03437928), an innovative approach to assess
patients with treatment refractory depression includes the use
of subacute invasive neurophysiological monitoring (i.e., stereo-
electroencephalography) to gain insight to the networks involved
in depressive symptomatology. The goal is to demonstrate and
to confirm the capability to selectively and predictably engage
distinct brain networks that are contributory to the pathologic
features of depression, and to demonstrate positive therapeutic
changes in such signs and symptoms through the use of network-
targeted stimulation.
The study included the use of directional current steering
DBS and individualized network targeting; with the aims of
demonstrating that this approach to targeting was feasible
and safe, and could possibly reduce depressive symptoms.
Targeting networks – instead of specific structures – might
prove to be crucial to individualizing therapies aimed at
modulating specific brain networks important to depression
(and other neuropsychopathologies). In this light, specific
network modulation may also be viable and of value in
treating obsessive compulsive disorder (OCD) (Banks et al.,
2015). Previously, a number of targets have been used to
treat OCD. Recent tractographic data show network-level
pathophysiology that can be targeted with DBS. It has been
reported that subdivisions of the anterior limb of the internal
capsule were found to vary substantially as viable targets for
DBS in treating OCD. However, some loci did prove to be
consistently useful targets, with the most notable effects being
produced by stimulating regions most densely connected to
the orbitofrontal cortex. Future studies are aimed at continuing
these investigations to (1) develop new technologies to delineate
symptomatic networks in neuropsychiatric disorders and (2)
to assess the effect of neuromodulation that targets different
networks and regions identified via advanced neuroimaging to
be participatory in depressive (and other psychiatric disorders’)
signs and symptoms.
Network Assessment in Movement Disorders
Given mounting evidence to support the possibility
of obtaining good clinical outcomes in the absence of
neurophysiological mapping – and multi-dimensionally
(e.g., clinically, technologically, economically); an important
question is what the future of intracranial neurophysiology
portends in an era of increasing use of real-time MRI-
guided and CT-verified DBS implantation in asleep patients.
One possibility is that network mapping, rather than
mapping of a single target structure, will be important to
improve the efficacy – and ultimate clinical effectiveness
and value of DBS. For instance, as evidence emerges for
separate networks that may be therapeutically responsive
to differential stimulation (e.g., speech, gait, non-motor
symptoms of PD) (Humphries and Gurney, 2012), techniques
will be needed to identify the optimal locations within these
networks for DBS placement. Additionally, if cortical sensors
[e.g., electrocorticography (ECoG)] become an important
component of closed-loop DBS systems, intraoperative
functional connectivity mapping of the target network may
be required for (optimized) placement of both sensing and
stimulating electrodes.
Opportunities for multi-scale, high-resolution neurophysio-
logical data collection are most robust intraoperatively, but
assessments are limited by available time and by the physical
constraints that restrict the complexity of behavioral tasks which
can be engaged (Figure 3). The use of simultaneous ECoG during
DBS implantation, however, can serve as a powerful tool for
identifying optimal network nodes. Using this technique, single
unit and LFP recordings from the target structure, as well as
LFPs from functionally connected areas of the cortex can be
simultaneously obtained (Panov et al., 2017). ECog has been
used to map pathological and physiological networks in PD
and dystonia. Additionally, (and perhaps of greater importance),
these studies have elucidated processes of information transfer
between the basal ganglia and cortex during limb movement
and speech production, which may afford information about
which signals are best suited for closed-loop DBS systems
capable of adapting to specific behavioral signs and symptoms.
Once a patient is implanted, intracranial neurophysiological
recording locations and modalities are fixed, but the subject can
participate in much longer trials of behavioral testing, either
in a subacute setting with externalized leads, or chronically
following implantation of a bi-directional pulse generator. Lastly,
functional imaging modalities can be used in multiple settings
facilitating longitudinal assessment. For example, pre-operative
MEG or fMRI data can be compared to those data obtained
in subacute or chronic post-operative periods in order to
measure target network engagement and other network effects of
stimulation over time.
Parametric Subtracted Post-ictal Diffusion Tensor
Imaging for Guiding Direct Neurostimulation Therapy
New techniques in tractography are being investigated as
methods which can be used to identify aberrant brain networks
and potential foci of epilepsy (Sivakanthan et al., 2016). Using
tractography to identify a specific ictal focus, implanting devices
for white matter modulation might afford benefit to those
epilepsy patients for whom other treatments are not viable.
Currently, the goal is to capture ictal and post-ictal states via
imaging tools in order to enable more individualized therapies.
The development and use of newer techniques will allow greater
precision in targeting domains of the refractory epileptogenic
network(s) (Nemtsas et al., 2017; Rossi, 2017). This will optimize
targeting and trajectories to access the involved network beyond
simply an anatomical target, to more fully and specifically
modulate the propagation pathway. Ongoing work aims to
utilize parametric methods to subtract post-ictal DTI to identify
such potential targets for modulation (Garibay-Pulido et al.,
2018). This technique has been helpful both for studying ictal
states and for identifying acute and chronic changes in network
activity in epilepsy patients. There are statistical differences
between pre- and post-seizure activity patterns that allow the
visualization of the epileptic network. From this visualization,
electrodes can be modeled into the DTI technique to reveal
probabilistic stimulation-induced network activations. To be
sure, these developments are promising, and additional steps
and validation, including fiber “cable modeling” via the use of
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FIGURE 3 | Intracranial neurophysiology opportunities for network assessment.
Hodgkin-Huxley equations, will be necessary and important to
validating and refining these methods.
Recent Advances in Neurophysiological
Signals for DBS
STN Recordings to Inform Closed Loop DBS in
Parkinson’s Disease
Resting state LFP neural recordings from the PD STN in intra- or
peri-operative studies have demonstrated exaggerated oscillatory
neuronal activity and synchrony in both the alpha (8–12 Hz)
and beta (13–30 Hz) bands (Maling et al., 2018). The extent of
attenuation of resting state beta band power during therapeutic
doses of both dopaminergic medication and high frequency (HF)
DBS has been correlated with improvement in bradykinesia and
rigidity. This suggests that STN resting state beta band power is
a physiological marker of PD and could be a potential control
variable for closed loop or adaptive (a)DBS. The resting state
beta band is conserved over time and across different resting
postures (Bronte-Stewart et al., 2009); it is similar between STN
nuclei; of greater power in more affected STN (De Solages et al.,
2010); it is a property of the functionally connected Parkinsonian
sensorimotor network; and its phase is coupled with gamma band
amplitude in the STN and M1 cortex (Whitmer et al., 2012). It is
attenuated during HF DBS and after washout of chronic STN DBS
(Whitmer et al., 2012; Trager et al., 2016); it is attenuated during
tremor, but it is not highly correlated to PD motor signs (Shreve
et al., 2017). Taken together, these findings prompt the question
of whether resting state beta band power is a validly good control
variable for aDBS in freely moving patients.
Apropos this question, it is now possible to record synchro-
nized neural and kinematic signals from an implanted sensing
neurostimulator and from wearable sensors respectively, in freely
moving human subjects (Activa R© PC + S, Medtronic, Inc., FDA
IDE approved). It has been demonstrated that the transition
from the resting state to a moving state (such as walking) is
associated with a change in the LFP spectrum, which was more
prominent in the akinetic rigid versus the tremor dominant
PD phenotypes (Quinn et al., 2015), and in PD freezers as
compared to non-freezers (Syrkin-Nikolau et al., 2017). Beta
band power during movement was attenuated in a voltage
dependent pattern during randomized presentations of differing
voltages of STN DBS (Whitmer et al., 2012). Different beta sub-
bands showed distinct sensitivities to attenuation during STN
DBS. Based upon this, it was investigated whether the more
or less sensitive sub-band was superior as a control variable
for aDBS (Afzal et al., under review). Temporal fluctuations
and the extent of unpredictable behavior of STN band neural
activity during movement (i.e., movement band) differentiated
PD freezers from non-freezers (Figure 4). Movement band burst
durations and entropy (i.e., sample entropy) were longer and
greater respectively in freezers compared to non-freezers during
gait without FOG, and were longer/greater in freezers compared
to non-freezers and during periods of FOG (Syrkin-Nikolau et al.,
2017). Temporal properties of the resting state beta band did
not differ between freezers and non-freezers. Longer movement
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FIGURE 4 | (A) Using LFP’s and neurophysiology to define and address freezing of gait in Parkinson’s disease. (B) Temporal fluctuations and the extent of
changeable behavior of STN band neural activity during movement differentiated PD freezers from non-freezers.
band burst durations and impaired gait improved during 60
and 140 Hz STN DBS in freezers, but short burst durations
and normal gait in non-freezers were unchanged. These results
suggest that gait impairment and FOG are characterized both by
more prolonged periods of pathological neural synchrony and by
unpredictability or chaos in STN beta rhythms, which disrupts
normal sensorimotor processing. The effect of STN DBS was
directed toward mitigating pathological neural activity related
to gait, and toward restoring greater physiological information
processing in the sensorimotor network, so as to improve gait and
FOG in PD freezers. This information affords new neural control
variables that may be more relevant in freely moving PD subjects
than the resting state beta band.
Pallidal and Cortical Recordings in PD: Prospects for
Pallidal Closed Loop DBS
There is increasing use of closed-loop DBS in PD, with most
groups utilizing STN signals as the neurophysiological marker
to enable aDBS. However, the globus pallidus interna (GPi) is
also an important locus in the pathological network of PD, and
is commonly targeted for the treatment of refractory motor
symptoms (Ramirez-Zamora and Ostrem, 2018). Investigating
potential pallidal and cortical signals might allow for reduction
of adverse side effects. Cortical signals have greater signal to noise
ratio than signals recorded from deep subcortical structures (De
Hemptinne et al., 2015). However, recent work has been focusing
on developing and characterizing pallidal interval recordings as
potential markers that can be studied in advanced, adaptable DBS
to improve tremor management in PD, reduce adverse effects
(including brittle responses, tolerance), reduce current drain, and
incorporate variability related to circadian rhythms (Swann et al.,
2018). Prior work has validated exaggerated oscillatory neuronal
activity and synchrony in the beta bands as a biomarker for aDBS.
Thus, current studies aim to improve the closed loop
algorithm and to analyze smaller windows of data to test
different refresh rates. Detector sophistication will be critical to
acquiring and assessing signals, and several critical questions
remain regarding whether to employ single threshold or center
frequency; the ideal rate of signal updates; ramp and onset times,
and the potential for energy savings, technical sources of variance,
long term benefit and signal reliability and reproducibility
afforded by this technique. Moreover, the increasing complexity
of these signals will likely require computerized or algorithmic
programing to mitigate long programing visits, and this
prompts questions and concerns about capability and use
of bio-informatic systems to facilitate these approaches (see
also above, re: bio-informatic systems development, progress
and challenges).
Adaptive Pedunculopontine Nucleus (PPN) DBS for
Treatment of Freezing of Gait
FOG affects approximately 78% of PD patients and is a major
cause of falls, and determinant of quality of life. Animal
research suggests that the GPi and PPN contribute to the
FOG in advanced PD (Thevathasan et al., 2018). Despite
several clinical trials reporting improvement in PD motor
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symptoms with DBS, treatment of FOG remains challenging.
PPN and PPN + STN DBS trials have been attempted for
management of refractory FOG, and have yielded mixed and
inconclusive findings (Thevathasan et al., 2018). A recent
study (NCT02318927) evaluated the feasibility and potential
effectiveness of closed-loop PPN for medication-refractory FOG
in patients with PD. Five (5) subjects with on-medication FOG
were implanted with bilateral open-loop GPi DBS to address
the cardinal PD motor symptoms. In addition, bilateral PPN
DBS was used as an adaptive closed loop strategy to specifically
address FOG. PPN recordings were precisely characterized and
utilized for measuring neural correlates to deliver responsive
stimulation. PPN low frequency power (1–8 Hz) tended to
increase during gait, while GPi beta frequency tended to decrease
during movement. Several challenges and complications were
encountered during the study, as consistent with other studies in
advanced PD patients. For example, recording signals were not
consistent in all electrode contacts or across both hemispheres.
But despite challenges, the study’s primary goal of improving
FOG was met, albeit with some limitation: the Closed loop-DBS
protocol produced a greater than 40% improvement in FOG at
6 months in a minimum of 3/5 subjects. However, adverse events
including scalp erosions and infections limited the feasibility of
Closed loop-DBS in all patients, and disease progression led to
worsening of motor and non-motor symptoms over time.
Thalamic and Cortical Signals for Development of
Closed Loop DBS in Essential Tremor
Closed-loop stimulation has similar efficacy to open-loop, and
in some contexts, closed-loop stimulation might be better than
traditional DBS (Little et al., 2016). Chronically implanted
sensing/stimulating devices (i.e., Activa RC + S) provide the
capability to acquire large volumes of diverse data in real-
life settings. These data can be useful in developing more
sophisticated, accurate and reliable biomarkers than those that
are currently available and used. Yet, closed loop-DBS also fosters
a number of questions that are, and will be, important to consider;
for example, is too much stimulation equally as problematic
as too little stimulation – and if so, in what ways? For which
diseases or disease states is closed loop-DBS best suited/most
effective? Can closed loop-DBS afford more specific cortical
biomarkers that can inform and guide improved modulation,
clinical outcomes, and reduced side/adverse effects?
The Medtronic Activa PC + S device enables the use of
a cortical strip for sensing/recording and a DBS electrode for
stimulation in the treatment of patients with refractory tremor.
The need for tremor control fluctuates greatly during the day
and theoretically, a closed loop system could minimize concerns
about side effects related to over- and/or under-stimulation (Kuo
et al., 2018). Investigators have employed a cortical strip placed
over M1, where beta power was used to trigger stimulation in the
thalamus using a dual threshold method and machine learning in
a subject-specific DBS model (Houston et al., 2019). Thresholds
were set to optimize and minimize under-stimulation (at the
relative calculated cost of over-stimulation). Assessments of
three (3) subjects performed by blinded clinicians demonstrated
that there was no significant difference in effectiveness between
open-loop and closed loop stimulation, although at least one
clinician evaluated spiral drawing by one subject to be better with
closed-loop stimulation. Using machine learning tools, ongoing
studies are attempting to define optimal parameters for open-
loop stimulation for a given patient. A voluntary brain computer
interface control method allows patients to control stimulation
for patient-driven mitigation of side effects [depending on the
function(s) being performed]. At present, it remains to be seen
how accurate detection of movement and/or intention by cortical
strips can be used to develop additional algorithms that can
shift depending on a patient’s functional state. Furthermore,
exploratory assessment revealed that patients’ feelings about
their relative agency and/or autonomy may differ depending
upon whether they have or do not have control over the level
of DBS stimulation. Preliminary findings suggest that patients’
sentiments vary widely (Gilbert, 2015).
Update on Brain Signals for Closed Loop DBS in
Parkinson’s Disease
Although DBS treatment of PD is an active field of research,
many of the initial challenges and limitations of these treatments
continue to be investigated. Meta-analysis of multiple DBS
studies showed great variability in lead location (Perestelo-
Perez et al., 2014). About one-third of implanted electrodes
are revised or removed, and about 50% of these are due to
suboptimal lead location. Lead localization and placement are
integral to the success of DBS treatment, and this remains
a challenge (Ellis et al., 2008). In part, this reflects varied
anatomical preferences for DBS electrode implantation between
neurosurgical practitioners and groups.
Thus, it becomes important to ask whether we really know
where the target is, and if it is the “best” target. For example,
in treating PD, tremor might be more responsive when the
STN is stimulated in one subregion, and bradykinesia may
improve more with stimulation of another subregion. In a recent
study, researchers attempted beta-triggered closed- loop DBS
in primates that were engaged in an acute reaching task. It
was found that greater improvements in rigidity were obtained
using closed- loop DBS (vs. traditional DBS), and that rigidity
improved more during certain aspects of the movement (Hendrix
et al., 2018). These results fortified the fact that biomarkers are
dynamic and can fluctuate depending on functional state (e.g.,
sleep vs. awake), and that multiple algorithms might be needed
to affect various target symptoms dependent on behavioral states.
Biomarker detection using machine learning control algorithms
might be required and may need to be adaptive over time
to compensate for neuroplasticity. Data collected from cortical
arrays implanted over M1 in primates showed that STN DBS
reduced cortical-subcortical coupling (Wang et al., 2017). During
off-DBS, the animal took longer to return to movement, but with
GPi DBS-ON, there was a pattern of re-synchronization during
the rest phase and de-synchronization during movement.
Evolving Neuromodulation Techniques
Temporal Interference and Deep Brain Stimulation
Boyden and Grossman recently developed a non-invasive
approach to electrically stimulating neurons at depth
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FIGURE 5 | Temporal interference as a non-invasive DBS technology.
(Grossman et al., 2017). By delivering multiple electric fields at
frequencies too high to recruit neural firing, but which differ by
a frequency within the dynamic range of neural firing, neurons
could be stimulated throughout a region wherein interference
between the multiple fields results in a prominent electric
field envelope that is modulated at the difference frequency.
This temporal interference (TI) was validated in modeling and
physics experiments, and these studies verified that neurons in
the living mouse brain could follow the electric field envelope
(Grossman et al., 2017). The utility of TI stimulation was
demonstrated in vivo by stimulating neurons in the mouse
hippocampus without recruiting neurons of the overlying cortex.
By altering the currents delivered to a set of immobile electrodes,
different motor patterns in living mice could be ‘steerably’
evoked (Figure 5).
Update on Coordinated Reset
Increasingly, data from both preclinical models and direct
recordings from patients undergoing DBS surgery support a
mechanistic role for changes in the presence and dynamics
of frequency-specific, synchronized oscillations across the
dopamine-depleted basal ganglia thalamocortical ‘motor’ circuit
(Nini et al., 1995; Brown et al., 2004; Mallet et al., 2008).
Coordinated reset (CR) is an experimental neuromodulation
paradigm engineered by Tass (2003) to desynchronize
‘pathological’ oscillatory activity across neuronal populations
through the intermittent, pseudo-randomized delivery of
brief, low-intensity, spatially-distributed pulse trains. A key
advantage of CR relative to traditional DBS is that its effects
should be achieved using lower individual pulse amplitudes
(Tass, 2003), as the goal of the spatiotemporally-randomized
stimuli is to break the otherwise hyper-synchronized target
region into multiple, independent clusters. It is believed that
an additional effect of this clustering phenomenon is to disrupt
spike-timing-depending plasticity that may be reinforcing the
persistence of the abnormal synaptic connectivity underlying the
development and persistence of pathological activity. The end
result being that even intermittent CR therapy may yield benefits
that outlast cessation of stimulation by hours or days (Tass, 2003;
Tass et al., 2012; Adamchic et al., 2014). From a therapeutic
standpoint, a major benefit of CR DBS is that it may reduce the
risk of provoking side-effects attributable either to the spread
of electrical current outside of the target region or to chronic,
continuous stimulation of the target itself (Ferraye et al., 2008;
Moreau et al., 2008; Van Nuenen et al., 2008; Xie et al., 2012),
and in these ways, reduce the overall duty-cycle of DBS delivery.
Hence, a CR DBS approach that involves the intermittent
delivery of low-intensity pulses may provide comparable motor
benefit but be less disruptive to cognitive, affective, and even
sensorimotor processing, while concomitantly reducing power
consumption requirements.
At this time, the potential of CR stimulation to mitigate
oscillatory activity is well-supported by theoretical models
(Hauptmann et al., 2007; Hauptmann and Tass, 2009; Guo and
Rubin, 2011; Lucken et al., 2013; Fan and Wang, 2015); however,
in vivo preclinical or clinical evidence of its effects has been
limited to three preliminary reports (Tass et al., 2012; Adamchic
et al., 2014; Wang et al., 2016). On-going studies involve the use of
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) non-
human primate model of parkinsonism to better understand the
acute, sub-acute and long-term efficacy profile of CR relative to
traditional DBS, as well as to define its effects on neural activity
across the basal ganglia thalamocortical motor circuit. The
continuing goal is to acquire data that will facilitate the design of
future human trials while further advancing an understanding of
the role of synchronized oscillations in individual parkinsonian
motor sign manifestation. The preliminary data acquired to
date are extremely supportive of a potential role for CR in
treating parkinsonian motor signs, but further point to potential
interaction between its effects and baseline motor severity, lead
localization, as well as the relative value of concurrent dopamine
replacement therapy. To be sure, successful implementation of
the CR DBS will require an effective re-dosing strategy to ensure
long-term stability of its therapeutic effects. Potential options
could range from open-loop strategies that involve applying CR
at regimented dosing epochs, to more physiologically-dependent,
demand-controlled approaches that are based on recordings
derived either from the DBS lead itself or from secondary
intracerebral recording arrays.
Advancing Applications of Optogenetic
Techniques to DBS
Deep Brain Networks and Circuits for Multiple
Behavioral States: Sleep, Arousal, Reward,
Locomotion, and Addiction
As reports from previous DBS Think Tanks, and a growing
body of international literature reveal, DBS can be a powerful
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FIGURE 6 | Bidirectional manipulation of cholinergic cells in the PPN exert opposing effects on locomotor behavior and reinforcement learning via specific
projections to the ventral substantia nigra pars compacta (vSNc) and the ventral tegmental area (VTA). This figure adapted from Cho et al. (2017).
therapeutic option for intractable movement and affective
disorders, with benefits often being dramatic and manifested
as instantaneous improvements in function and/or pathologic
presentation. However, because electrical stimulation is non-
specific, the mechanisms underlying or involved in the effects
of DBS remain less than fully understood, and in some cases,
are a source of controversy. The application of optogenetics to
DBS challenged the traditional perception that DBS in the STN
acts mainly by inhibiting local cell bodies at the stimulation site.
Optogenetics uses genetically encoded, light-sensitive proteins to
modulate or monitor the function of specific cell types within
living heterogeneous tissue. In one of the first demonstrations of
the power of optogenetics, we showed that control of axons in
the stimulation area was sufficient to restore motor behavior in
PD models (Gradinaru et al., 2009).
At least partly based upon these findings, a number of
other targets for DBS are now being investigated for various
indications. Examples include the neuromodulatory circuitry of
two deep brain regions, the cholinergic mesopontine tegmentum
[comprising the PPN and the laterodorsal tegmentum (LDT)]
and the dopaminergic neurons of the dorsal raphe nucleus
(DRNDA) (Xiao et al., 2016). The use of neurotechnology
revealed details of both circuits that may ultimately lead to
new therapeutic targets for movement and addiction disorders
(PPN circuits), and sleep/arousal disorders (DRNDA circuits)
(Figure 6). Bidirectional manipulation of cholinergic cells in
the PPN exerts opposing effects on locomotor behavior and
reinforcement learning via specific projections to the ventral
substantia nigra pars compacta (vSNc) and the ventral tegmental
area (vTA). Additionally, DRNDA activity increases in response
to salient stimuli irrespective of valence, is correlated with sleep–
wake states, and can bi-directionally modulate arousal.
Sleep and arousal modulation
The ability to awaken in response to salient stimuli and to
remain alert when awake, particularly upon perception of
relevant environmental danger or crying offspring, holds obvious
biological importance in terms of survival and fitness of self, kin,
kith, and/or species. Our work using mouse models suggests that
DRNDA neurons play a key role in this process (Cho et al., 2017).
Using simultaneous fiber photometry and polysomnography
(EEG/EMG), time-delineated DRNDA activity upon exposure to
arousal-evoking salient cues, irrespective of hedonic valence, was
observed. As well, fluctuations of DRNDA activity across sleep–
wake cycles were seen, with highest activity during wakefulness
versus sleep states. Both endogenous and optogenetically
driven DRNDA firing were associated with arousal from sleep
(Figures 7, 8). Conversely, chemogenetic DRNDA inhibition
opposed wakefulness. Finally, time-locked DRNDA inhibition
reduced the probability of an immediate sleep-to-wake transition
upon delivery of an unconditioned tonal stimulus.
Cumulatively, these data suggest that DRNDA neurons
modulate arousal and can promote awakening by salient stimuli.
While the ability to rouse from sleep in response to alerting
stimuli is an evolutionarily conserved survival strategy, it may
have negative sequelae in modern human populations: insomnia
or hypersomnia triggered by malfunctioning arousal-promoting
circuits is a morbid societal burden (Roth, 2007). Going forward,
strategies targeting DRNDA activity may have utility both in
the treatment of primary sleep–wake disorders and sleep/arousal
disturbances secondary to myriad neuropsychiatric diseases,
including depression, bipolar disorder, and schizophrenia.
Modulation of reward
The mesopontine tegmentum provides major cholinergic inputs
to the midbrain and regulates locomotion and reward. To
delineate underlying projection-specific circuit mechanisms,
we employed optogenetics to control mesopontine cholinergic
neurons at the somata and at divergent projections within distinct
midbrain areas. Bidirectional manipulation of cholinergic cell
bodies in the PPN exerted opposing effects on locomotor
behavior and reinforcement learning. Motor and reward effects
were separated by limiting photostimulation to PPN cholinergic
terminals in the vSNc or in vTA, respectively. LDT cholinergic
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FIGURE 7 | Endogenous and optogenetically driven DRNDA firing. (A) TH-Cre mice were injected with AAV5-Syn-FLEX-GCaMP6f or AAV5-hSyn-DIO-EGFP and
implanted with an optical fiber into the DRN for fiber photometry. (B) Confocal images of GCaMP6f+ (green) neurons show co-localization with TH+ neurons (red),
but no overlap with 5-HT+ neurons (blue). Scale bar, 100 µm. (C) Social interaction between a male DRNDA-GCaMP6f resident mouse and a female intruder were
associated with increased DRNDA activity; the trace is a representative recording with interaction bouts indicated. (D) Left: female interaction caused an increase in
fluorescence at the onset (first interactions only). Right: quantification of the area under the curve per second (AUC) during the interaction (0–5 s) shows that social
interaction caused significant increase in DRNDA activity from baseline (−5 to 0 s) (n = 7 DRNDA-GCaMP6f mice; paired t test, t6 = 11.97, ∗∗∗p < 0.001). (E) Chocolate
consumption by a DRNDA-GCaMP6f mouse increased DRNDA activity; representative recording. (F) Left: DRNDA activity was increased upon chocolate consumption.
Right: AUC quantification during consumption (0–5 s) compared with baseline (−5 to 0 s) shows that food consumption is associated with significant fluorescence
increase (n = 7 DRNDA-GCaMP6f mice; paired t test, t6 = 4.273, ∗∗p < 0.01). (G) Electric footshocks (0.25 mA, 1 s) were delivered; representative DRNDA trace during
two consecutive footshocks. (H) Left: footshock induced phasic DRNDA activation. Right: DRNDA activity after footshock (0–5 s) was significantly increased relative
to baseline (−5 to 0 s) (n = 7 DRNDA-GCaMP6f mice; paired t test, t6 = 5.763, ∗∗p < 0.01). (I) Peak DRNDA fluorescence values during female interaction, chocolate
consumption, and electric footshocks were significantly higher than those during novel and familiar object interaction (n = 7 DRNDA-GCaMP6f mice; one-way ANOVA,
F4,30 = 22.77, p < 0.0001, Bonferroni post hoc analysis, ∗∗∗p < 0.001).
FIGURE 8 | Dorsal raphe nucleus dopaminergic (DRNDA) activity escalates in response to salient stimuli irrespective of valence; correlates with sleep–wake states,
and can bidirectionally modulate arousal. (A) Experimental paradigm. (B) Auditory cues are associated with time-locked increases in DRNDA activity. (C) DRNDA
activity increase, as indexed by the difference in the area under the curve between before and after tone presentation, was larger when auditory tone induced
sleep-to-wake transitions than when it was turned on while awake or when it failed to cause sleep-to-wake transitions (n = 7 DRNDA−GCaMP6s; One-way ANOVA,
F2,18 = 10.79, p < 0.001, Post hoc Bonferroni analysis, ∗∗p < 0.01). (D) Experimental paradigm. (E) Time-locked DRNDA inhibition decreased the probability of
NREM-to-wake transitions upon auditory cues (n = 6 DRNDA−Arch, n = 4 DRNDA−eGFP; Two-tailed, unpaired t-test, ∗∗∗p < 0.001. (F) No significant change in the
probability of REM-to-wake transitions (n = 6 DRNDA−Arch, n = 4 DRNDA−eGFP; Two-tailed, unpaired t-test, p > 0.1).
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neurons also form connections with vSNc and vTA neurons;
however, although photo-excitation of LDT cholinergic
terminals in the vTAc aused positive reinforcement, LDT-to-
vSNc modulation did not alter locomotion or reward. Therefore,
the selective targeting of projection-specific mesopontine
cholinergic pathways may offer increased benefits in treating
movement and addiction disorders.
Optogenetic Techniques to Facilitate Modulation of
Motor Circuits
The identification of distinct cell types in the basal ganglia has
been critical to an understanding of basal ganglia function and
the treatment of neurological disorders. The external globus
pallidus (GPe) is a key contributor to motor suppressing
pathways in the basal ganglia, yet its neuronal heterogeneity has
not been engaged as a resource for therapeutic interventions.
Optogenetic techniques may enable cell specific identification
and stimulation of GPe networks that can be modulated by
DBS (Gittis et al., 2014). The indirect pathway is overactive
in PD and suppression of GPe neurons using these techniques
might both increase activity in GPe and improve movement.
However, experiments in mouse models failed to demonstrate a
clear benefit in motor symptoms. In recent studies, optogenetic
interventions that dissociate the activity of two neuronal
populations in the GPe, elevating the activity of parvalbumin
(PV)-expressing GPe neurons over that of Lim homeobox 6
(Lhx6)-expressing GPe neurons, reinstates movement in DA-
depleted mice, and decreases pathological activity of basal ganglia
output neurons for hours past stimulation (Mastro et al., 2017).
These results establish the utility of cell-specific interventions
in the GPe to target functionally distinct pathways, with the
potential to induce long-lasting recovery of movement despite the
continued absence of DA.
The Use of Optogenetics to Understand Addiction
Circuitry
Addiction can be regarded – at least to some extent – as a
neural circuit disorder; functional imaging has identified the
cortico-accumbal-pallidal network as a locus of altered resting
state connectivity in patients with addiction, and the nucleus
accumbens (NAc) has been proposed as a target for DBS
(Figure 9). NAc-DBS suppresses drug seeking and sensitization
to drug-associated cues, although these behavioral effects are
transient, and paradoxical increased substance consumption has
been observed (Hadar et al., 2016; Creed, 2018). Moreover,
a better understanding of the underlying mechanisms of the
NAc-DBS may be useful for optimizating stimulation protocols.
Understanding mechanisms underlying altered functional
connectivity in addiction could be leveraged to design targeted
neuromodulation protocols to normalize circuit function and
abolish behaviors associated with addiction. For example,
cocaine exposure potentiates prefrontal cortical inputs to
the NAc via the insertion of calcium-permeable AMPA
receptors, and optogenetically driving these inputs between
10 and 15 Hz triggers a signaling cascade that reverses this
synaptic potentiation and abolishes drug sensitization and
seeking (Pascoli et al., 2011). Based on these observations,
an optogenetically-inspired DBS (OiDBS) protocol was
developed; this protocol combined 12 Hz stimulation with
a D1 dopamine receptor antagonist (Creed et al., 2015). The
D1R antagonist was necessary to prevent D1R-dependent
signaling which inhibits de-potentiation. OiDBS normalized
synaptic transmission and reduced locomotor sensitization
following cocaine exposure. If translated to humans, an OiDBS
protocol would have several advantages over traditional DBS
protocols. It would significantly reduce stimulation time, which
would extend battery life and/or could be instrumental to
non-invasive stimulation methods. Stimulation protocols could
also be tailored to normalize circuit function associated with
diverse symptoms of addiction, such as craving vs. withdrawal-
induced negative affect. To this end, neural signatures of
behavioral symptoms would need to be identified. Recording
from multiple sites and using altered synchrony across brain
areas to trigger DBS in a closed-loop manner would represent
a major therapeutic advance. Further, the use of OiDBS could
extend beyond addiction to other disorders characterized by
altered function of neural circuits, such as chronic pain, mood,
and neurodevelopmental disorders.
Use of Optogenetics in Alzheimer’s Disease Circuitry
While neural stimulation has opened up a new class of
therapeutics for a number of neurological and psychiatric
diseases, there has been little work to examine how such
stimulation could be used to treat Alzheimer’s disease (AD),
the most common form of dementia. The lack of research on
neural stimulation in AD likely stems from the fact that little
is known about how neural activity fails in AD or how neural
activity affects molecular pathology. Therefore, to determine how
brain stimulation could potentially be used to treat AD, we
identified deficits in neural activity in mouse models of AD and
determined the effects of neural stimulation on molecular and
cellular pathology (Iaccarino et al., 2016).
Because spatial navigation deficits are one of the earliest
symptoms of AD and the hippocampus is one of the
neuroanatomical areas first affected by the disease, we examined
how hippocampal neural activity changes in AD (Fox et al., 1996;
Deipolyi et al., 2007). Using a virtual reality behavior paradigm
to record and manipulate neural activity in transgenic mice, the
primary animal model of AD, deficits in hippocampal neural
activity were revealed early in the progression of the disease.
These deficits occurred in the same patterns of activity that
we and others previously found to be involved in memory-
guided decisions in spatial navigation tasks (Carr et al., 2012;
Pfeiffer and Foster, 2013; Singer et al., 2013). Subsequently, we
found that driving gamma activity, which is lacking in AD mice,
mobilized the immune system to remove pathogenic proteins.
Specifically, driving 40 Hz neural activity via optogenetic
stimulation recruited microglia -the primary immune cells of the
brain – to alter their morphology and increase engulfment of β
amyloid, a protein thought to be involved (if not initiate) a series
of neurotoxic events in AD (Iaccarino et al., 2016).
To achieve the same effects non-invasively, we harnessed
the neural circuits’ natural tendency to respond to sensory
stimuli. While extensive prior work has shown that flickering
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FIGURE 9 | Approaches to Addiction DBS.
lights and sound stimuli drive neural activity at specific
frequencies in sensory cortices, we have found such flickering
sensory stimuli can also drive specific frequencies of neural
activity in deeper brain structures, including the hippocampus,
albeit with more modulatory effects (Iaccarino et al., 2016).
Using this approach, we demonstrated that flickering stimuli
within gamma frequencies, 40 Hz in particular, drives gamma
frequency neural activity in hippocampus and recruits microglia
to engulf pathogenic proteins in mouse models of AD. Existing
methods for stimulating neural circuits with temporal precision
are either invasive (e.g., DBS), or only access superficial
brain structures [e.g., transcranial electrical stimulation (tES)].
Frontiers in Neuroscience | www.frontiersin.org 14 September 2019 | Volume 13 | Article 936
fnins-13-00936 September 10, 2019 Time: 18:4 # 15
Ramirez-Zamora et al. Sixth DBS Think Tank Proceedings
Thus, the demonstration that flickering sensory stimuli drives
rhythmic neural activity in deep structures reveals a new, and
potentially powerful non-invasive tool with which to modulate
and/or manipulate neural activity. Moreover, the discovery that
stimulating neural activity at specific frequencies can recruit
immune cells in the brain to reduce molecular and immune cells
may afford a new potential use of neural stimulation to treat
certain forms of neuro-psychiatric disease.
Novel Databases for DBS and
Neuroimaging Stereotactic Techniques
CranialCloud
The use of complex, heterogeneous, multi-level and -dimensional
data is -and will increasingly be – crucial to realizing the
potential of a number of neurotechnologies and their use
in clinical practice (DiEuliis and Giordano, 2016). Rapidly
advancing technology in healthcare informatics is providing
increasing opportunities for innovative strategies in both the
clinical management of patients, and the advancement of
research. As informatic technology is more widely adopted into
clinical practice, increasing opportunities – and challenges –
arise in the collection, storage, analysis, interpretation,
and use of ever larger and more multi-dimensional data
resources. Many laboratories throughout the world are
using varied imaging and neurophysiologic techniques to
address research questions and the translation of positive
experimental findings into clinically viable methods. Inter-
institutional collaboration (on both intra- and inter-national
scales) requires standardization of the data collection process
and effective and efficient means of data sharing. However,
much of the collected data is stored locally, and sharing
capabilities are either expensive, inefficient, or unavailable.
Therefore, it will be important to develop improved methods
for facile exchange of information between large datasets and
patient cohorts.
Cranial Cloud engages this opportunity by providing a
platform to standardize data collection and storage (D’haese
et al., 2015). This program is equipped with tools to process,
analyze and share data in a de-identified manner. Similar in
design to the DropBox model, the Cranial Cloud system is capable
of integrating information with currently available and widely
used electronic medical record systems (e.g., EPIC). Clinical
assessments and anatomical/imaging data can be collected in
a standardized method in order optimize compatibility with
various atlases and programs. The overall goal is to maintain
and advance normalized, consistent and efficient data collection,
sharing and analysis soas to both reduce (if not eliminate)
constraints imposed by existing systems, and to avoid the time
and economic costs of duplicative analyses. Questions remain
about the funding source of such an endeavor, but it will
likely require collaboration between academic, corporate and
government institutions. Concerns about data sharing with third
parties will be a challenge for ensuing technologies.
Blackfynn
National Institutes of Health policy states that data should
be widely and freely available, while still maintaining privacy
and confidentiality1. In keeping with this policy, the Blackfynn
Scientific Platform functions to standardize data collection in
DBS patients, and to make these data more accessible in
accordance with existing regulations for data sharing2. As well,
this platform can maintain data that would otherwise be lost
due to cessation of funding. Blackfynn aims to develop a strong
business model to sustain the database independently of short-
term funding. This database will enable improved workflow and
medical record integration that will appeal to clinicians and
researchers. A major feature of the program is its web-based,
high performance computing capability, which allows users to
maintain possession of their data while simultaneously using the
platform for data analysis.
One example of such successful data collection, storage and
sharing is the Parkinson’s Progression Markers Initiative (PPMI),
which facilitates rapid exploration and data-driven analysis,
rather than exclusively utilizing a hypothesis-driven approach.
This database can also be combined with other backgrounds
and datasets to examine biomarker overlap and/or to integrate
genetic or physiologic data, and can facilitate cooperation and
collaboration between the academic and corporate sectors, and
can positively impact and be implemented by a variety of
stakeholders, including foundations and advocacy groups. These
collaborations are – and will be ever more – essential given the
resource demands for the sustenance and iterative expansion and
improvement of such a large database.
Surgical Information Sciences
The neurosurgical implantation of DBS systems requires a
high degree of accuracy in placing electrodes at the identified
target sites, and clinical outcomes greatly depend upon the
precise localization of special leads and contacts (Ellis et al.,
2008). For example, suboptimal STN electrode placement
has been associated with reduced clinical efficacy and the
occurrence of adverse effects. At present, all candidates for
DBS implantation surgery undergo 1.5 (i.e., structural) and/or
3 Tesla (T; functional) magnetic resonance imaging (MRI)
as a component of the presurgical clinical workup. With the
widespread availability of MRI devices for clinical use, direct
targeting (i.e., targeting that is based on visually identifying
the intended sites of electrode placement) has become more
feasible. However, standard clinical MRI protocols are typically
associated with low resolution, inadequate image contrast and
relatively low signal to noise ratio (SNR), which make accurately
identifying the intended anatomical targets difficult. As a result,
it can be challenging to identify the exact borders of the
intended targets, and differentiate DBS targets from adjacent
anatomical structures.
Ultra-high field (UHF) MR acquires images using a generated
magnetic field that is equal to or greater than 7T (Abosch
et al., 2010). 7T MRI has proven to provide structural images
of the human brain with rich informational content, higher
contrast and resolution, and with the potential for use in clinical
applications (Duchin et al., 2012, 2018; Gunalan et al., 2017).
1https://grants.nih.gov/grants/policy/data_sharing
2https://www.blackfynn.com
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FIGURE 10 | Patient specific modeling for DBS.
The enhanced images acquired using 7T systems improve
the ability to visualize subcortical structures, and to create
patient-specific 3D anatomical models. This is important given
that there is significant variability across individuals in the
location, volume, length, depth, and width of a number of
neuroanatomical structures (e.g., the STN). The use of patient-
specific 3D anatomical models using pre-operatively acquired
7T MRI data can be combined with post-operative imaging
(CT or MRI) to create computer-generated depictions of DBS
electrode position and contacts (Duchin et al., 2018) (Figure 10).
Additionally, the use of diffusion weighted images and structural
connectivity-based parcelation protocols can enable depiction of
STN connections to the motor, limbic, and associative cortical
areas, which can be used to map the individual subdivisions of
the nucleus (Plantinga et al., 2018). These new capabilities suggest
that the use of 7T MR imaging may facilitate individualized and
highly specific planning of DBS implantation of the STN, as well
as other DBS targets (Patriat et al., 2018; Shamir et al., 2019).
Our ongoing work is focused upon exploring these capabilities
in further detail.
Neuroethical, Legal, and Social Issues
(NELSI) in DBS
Continued Access to Investigational Brain Implants
and Care
At the most fundamental level, the aim of development and use of
brain implants has been to enable successful intervention against
treatment-resistant neurological and psychiatric disorders.
Although the underlying rationale and goals of invasive
neuromodulation were and remain benevolent, implantation
of these devices exposes patients to both the inherent risks of
neurosurgery and to the burden and risks incurred through the
use of novel technology (Giordano, 2015a). There is growing
discourse about if and how DBS systems should be removed
(i.e., explanted) if satisfactory or durable clinical outcomes are
not achieved, or if deleterious/adverse effects are incurred. Most
trials include plans for explantation for those patients who do not
receive benefit or who may have adverse effects, but generally,
the cost of explantation surgery is not covered. This is not unique
or surprising, given that other incurred costs (e.g., unscheduled
visits to the clinical specialists, battery replacement, device
repairs, salvage procedures due to infection) may – and often –
also are not covered (Rossi et al., 2017).
To date, such issues have been addressed on a case-by-
case basis. In the United States there is no legal obligation
to provide continued access to DBS devices or resources. Yet,
given that the majority of DBS implantation is undertaken
as either a large scale clinical trial, or as a component of
investigator initiated research (IIR) studies, the constructs of
the Declaration of Helsinki could be utilized to support and
reinforce continuity of care under as a component obligation of
protecting the best interests of the patient/subject – both during
and as a consequence of the research study – as constituent to
the conduct of responsible research (Giordano, 2015b, 2016).
The strength of the moral obligation to provide continued
provision of, and access to care depends on the vulnerability of
patients, the burden placed on them by the research protocol
(e.g., lack of treatment options, and imperatives to advance these
technologies), and the feasibility of providing continued clinical
care without unnecessarily impairing or impeding ongoing or
future research.
Indeed, costs of establishing, and supporting continued care
could substantially constrain certain sponsors’ ability to pursue
research. In turn, such constraints could negatively impact both a
sponsor’s engagement in and support of further research, and the
potential benefits that such research could provide to the extant
and future recipient patient populations at-large. Recent requests
for proposals (RFPs) issued via the National Institutes of Health’s
programs within the US Brain Research through Advancing
Innovative Neurotechnologies (BRAIN) Initiative have mandated
that researchers describe the plan for the patient at the end of the
study period, and the ethical principles supporting an extended
(albeit) limited duty of care beyond the research protocol. More
specific language is being considered for incorporation into
current and future RFPs. But any meaningful discussion of
ethics must acknowledge and address economic issues, and so
consideration of continued care as a constituent of responsible
research must be inclusive of cots and coverage of provision and
access, time period of extended care, availability of treatment
options and alternatives, development of novel treatments, and
the systems in place and operational in order to accommodate
the fiscal burdens of such needs and demands.
Toward Ethical Integration in the Development and
Use of DBS
Perhaps one of the more provocative, if not contentious ethico-
legal questions is whether DBS “changes” personality, the
“self ” and in these ways, impairs patient individual autonomy
(Jotterand and Giordano, 2011; Giordano, 2015b). As well,
there are concerns about patients’ and families’ psychological
effects and reactions to living with the device; the effect of DBS
on patients’ social relationships; and to broader influence that
DBS – and other neuromodulatory technologies – will incur
upon and within society and culture. The question of whether
stimulating brains is a form of “mind control” and “creating
new selves” is gaining prominence as a focus of discourse, both
within medicine and the social sciences, as these technologies
and techniques are being both considered for the treatment
of a broader palette of neurological and psychiatric disorders,
and viewed toward the potential to modify cognition, emotion
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FIGURE 11 | Perspectives and Attitudes Toward DBS. An anonymous 40 question poll was sent online to assess participants’ perspectives and attitudes toward the
current and near-term future developments and applications in the DBS field. Sixty six participants responded.
and behavior in “cosmetic,” socio-politically and/or military
contexts and ways. Looking – and moving – ahead, qualitative
and behavioral studies in natural environments will likely be
increasingly necessary to more fully elucidate the ways that DBS
(and other neuromodulatory technologies) can, should, or should
not be developed and used to mitigate or prevent the effects of
disease and injury, and/or improve the quality of life.
Moreover, defining “advancement” and “improvement” to
establish the groundwork for ongoing research, development and
use-in-practice will be essential to a prudent approach to DBS
in this era of personalized medicine, global health initiatives,
healthcare and technological inequalities, and the expansion of
multi-national research and medical tourism opportunities. In
this light, such discourse must be international and sensitive,
if not responsive, to differing cultural perspectives, needs,
philosophies, values, and capabilities (Stein and Giordano, 2015;
Giordano, 2018). We have previously advocated for “no new
neuroscience without neuroethics” and “no neuroethics without
neuroscience” (Giordano and Shook, 2015), as ethico-legal and
social discourse and decisions must be based upon and proceed
from the realistic capabilities conferred by the science and
technology. Here, we widen our invocation to appeal for a multi-
cultural lens, discourse and engagement soas to fortify scientific
and technological developments with a fuller depiction and
consideration of the socio-cultural contexts and realties that may
shape and be shaped by the use of DBS on the world stage.
SUMMARY AND CONCLUSION
The field of neuromodulation continues to evolve and ongoing
research will shape the scientific landscape. This manuscript
represents the views of the participants of the think tank and
does not consider all the literature on the topics discussed.
As in prior years’ meetings, an anonymous 40 question poll
was sent online to evaluate participants’ perspectives and
attitudes toward the current and near-term future developments
and applications in neuromodulation. Sixty six participants
responded. Figure 11 summarizes these responses and
compares them to last year’s responses. It is notable that
some applications moved to the trough of disillusionment
(e.g., DBS for depression), others moved to the peak of
inflated expectations (e.g., Vagus nerve stimulator for heart
failure), and others remained on the slope of enlightenment
(DBS for Parkinson’s, DBS for essential tremor, cochlear
implants, and VNS for epilepsy). Consistently, the use of
DBS for movement indications has reached the plateau of
productivity and among most Think Tank participants there
was cautious optimism regarding the use of larger network
based modulation. There was also cautious optimism for
advancing neurophysiological and anatomical signals to improve
neuromodulation for several neuropsychiatric conditions,
non-neurological indications. There was clear optimism for the
development of novel technologies.
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